Claim Missing Document
Check
Articles

Found 2 Documents
Search

Estimasi Biaya Pengobatan Langsung Penyakit Kanker Di Indonesia: Estimasi Direct Medical Cost (DMC) Yuni Andriani; Susi Ari Kristina; Chairun Wiedyaningsih
Majalah Farmaseutik Vol 17, No 3 (2021)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v1i1.49823

Abstract

Kanker adalah salah satu penyakit tidak menular dan merupakan penyebab mortalitas tertinggi di berbagai belahan dunia. Berdasarkan perkiraan Globocan, International Agency for Research on Cancer (IARC)  tahun 2018, ada lebih dari 18 juta kasus baru kanker di seluruh dunia, dan jumlah ini diproyeksikan meningkat lebih dari 61% pada tahun 2040. Di Indonesia, Riset Kesehatan Dasar (Riskesdas) tahun 2018 memperlihatkan prevalensi kanker meningkat dari 1,4 persen di tahun 2013 menjadi 1,8 persen di 2018. Selain itu, di Indonesia dari seluruh penyakit yang menyebabkan kematian, kanker menempati peringkat ketujuh dengan presentase 5,7%. Prevalensi kanker 1,4 per 1000 penduduk atau sekitar 330.000 orang. Penelitian ini bertujuan mengestimasi total biaya pengobatan langsung pasien dengan penyakit kanker dan mengetahui angka kejadian kanker yang paling tinggi di Indonesia. Hasil penelitian menunjukkan bahwa jenis kanker dengan angka kejadian tertinggi, yakni kanker serviks 31.9% (250.654 kasus), kanker kolorektal 21.4% (168.013 kasus), dan kanker ovarium 11.7% (92.076 kasus). Total biaya pengobatan langsung 14 jenis kanker di Indonesia berdasarkan data klaim BPJS secara keseluruhan pada tahun 2018 adalah sebesar Rp1.4 miliar. Jenis kanker dengan beban biaya tertinggi yakni kanker serviks sebesar Rp393 juta (27.03%), kanker kolorektal Rp335 juta (23.07%), dan kanker ovarium Rp168 juta (11.57%). 
Pengaruh Kepatuhan Minum Obat terhadap Pengendalian HbA1c pada Pasien Diabetes Melitus Tipe 2: Tinjauan Sistematis Berdasarkan Metode Pengukuran Kepatuhan Ina Kusuma Diana; Chairun Wiedyaningsih; Fivy Kurniawati
Journal of Pharmaceutical and Sciences JPS Volume 9 Nomor 1 (2026)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v9i1.1415

Abstract

Type 2 diabetes mellitus (T2DM) is a major public health concern in Asia, where rapid urbanization and lifestyle changes have contributed to a marked increase in disease prevalence. Poor medication adherence remains a major barrier to achieving optimal glycemic control, leading to an increased risk of complications and greater healthcare burden. This systematic review aimed to examine the relationship between medication adherence and glycated hemoglobin (HbA1c) levels among patients with T2DM, compare the strength of this association across different adherence measurement methods, and identify key factors influencing adherence and glycemic control in Asian populations. A literature search was conducted in PubMed, Europe PMC, Scopus, and ScienceDirect for cross-sectional studies published between January 2015 and April 2025. Eligible studies included adult patients with T2DM who reported medication adherence (e.g., MMAS-8, pill counts) and HbA1c outcomes. Data were synthesized narratively, and study quality was assessed using standardized appraisal tools. Of the 584 records screened, 14 studies met the inclusion criteria. Most studies demonstrated a significant inverse association between medication adherence and HbA1c levels, with stronger associations observed when objective or multidimensional adherence measures were used. Reported adherence levels varied substantially across studies, with the proportion of high adherence ranging from 3.7% to over 58%, depending on the measurement method. Mean HbA1c values ranged from 6.4% to 9.2%. Higher educational level, greater self-efficacy, and supportive healthcare environments were associated with better adherence. In contrast, psychological distress, regimen complexity, and comorbidities were linked to lower adherence and poorer glycemic control. Medication adherence is a critical determinant of glycemic control among patients with T2DM in Asia. The choice of adherence measurement method influences the observed association with HbA1c. Interventions should address psychosocial and clinical barriers and incorporate culturally adapted, multidimensional adherence assessment approaches.